Smart Money Circle

Adam Sarhan

This show interviews the “smart money” (large money managers & CEOs) for timeless investing advice. My goal is to provide you with timeless/actionable advice that you can use to make smarter investment decisions, and help you become intellectually wealthy. The Host: Adam Sarhan, Author, Investor, and Forbes Contributor, interviews real money managers with over $100 million in assets under management (AUM) and CEOs for timeless advice. Disclaimer: All our work is general in nature and for educational/informational purposes only. No specific investment advice is given.

  1. 1d ago

    $3 Billion Money Manager Never Interrupt Compounding – Isaac Wakszol CEO Activest Wealth Management

    Guest Isaac Wakszol is the CEO of Activest Wealth Management Company Activest Wealth Management Website https://activestwm.com/ Assets 3B AUA 1.7B AUM Isaac’s Bio Before founding Activest, he represented a Swiss private investment bank in Venezuela, gaining valuable international finance insights. His academic credentials include a civil engineering degree from Universidad Metropolitana and an MBA from IESA Venezuela and Babson College. Fluent in English and Spanish, he holds a Series 65 license, reflecting his deep commitment to financial services. As Founder and CEO of Activest Wealth Management, he leads with a focus on strategic initiatives, investment management, and enhancing client relationships. His extensive experience in the financial sector began in 1996, shaping his skills in portfolio management and financial planning, both domestically and internationally. Outside of his professional endeavors, he is an avid runner and an active member of the Jewish community in Aventura, Florida, where he has been residing since 2008. His commitment extends beyond business to include significant community and family engagements, making him a well-rounded leader and influencer in both his professional and personal life. Company Bio: We provide personalized financial advisory services through a skilled, passionate team dedicated to transforming your financial experience from a human perspective.

  2. 2d ago

    Is Lidar The Future Of Autonomous Driving? Meet Matt Fisch CEO AEYE $LIDR

    This CEO Is Using Lidar To help Autonomous Driving- Meet Matt Fisch CEO AEYE $LIDR Matt Fisch Chairman & Chief Executive Officer, AEye, Inc. $LIDR Matt Fisch is Chief Executive Officer of AEye, Inc. (NASDAQ: LIDR), a global leader in adaptive, high-performance lidar solutions for automotive, trucking, intelligent transportation systems, and smart infrastructure applications. He brings decades of executive leadership experience across the automotive technology, mobility, and industrial sectors, with a strong track record of scaling technology businesses, driving commercial growth, and leading strategic transformations. As CEO, Matt is focused on accelerating AEye's commercialization strategy, expanding strategic partnerships, and delivering next-generation sensing solutions that enable safer, smarter, and more autonomous transportation. Company: AEye, Inc. (NASDAQ: LIDR) https://www.aeye.ai Bio AEye is a global leader in adaptive, high-performance lidar technology designed to help vehicles and infrastructure perceive the world with greater precision, range, and intelligence. Its software-defined lidar platform delivers long-range detection, rapid response times, and dynamic adaptability for automotive, commercial trucking, intelligent transportation systems, and smart infrastructure applications. By combining advanced sensing with AI-driven perception, AEye enables safer mobility, supports autonomous driving innovation, and enhances traffic management and road safety worldwide. To learn more, visit https://www.aeye.ai

  3. Oct 7

    VC Investments In A Publicly Traded Fund? Meet Dr. Naj – CEO C1 Fund - $CFND

    VC Investments In A Publicly Traded Fund - Meet Dr. Naj – CEO C1 Fund - $CFND Guest Dr. Najamul Kidwai, Co-Founder, President, and Chief Executive Officer C1fund --CFND Najam Kidwai - Company C1 Fund (NYSE: CFND) www.c1fund.com Guest Bio Dr. Kidwai is a seasoned entrepreneur, investor, and operator with a deep passion for innovation and emerging technologies. As a co-founder, he has served as President, CEO, and Director of the company since its inception, helping shape its strategic vision from the ground up. He brings a rich track record of building and backing transformative ventures. From 2021 to 2022, Dr. Kidwai served as Chairman and Director of Crypto 1 Acquisition Corp, a SPAC focused on digital assets, blockchain, and crypto infrastructure, where he led a successful $230 million raise. He is also a Venture Partner and Investment Committee Member at Frontier Ventures, an early-stage venture fund investing in next-gen tech and blockchain startups. Since 2017, Dr. Kidwai has been a co-founder and Executive Committee member of EQUIAM, a leading venture capital fund focused on private markets. Through EQUIAM and other platforms, he has invested in a wide range of pioneering companies, including TransFi, Klickl, Forge Global, and Destiny XYZ, among others. He continues to actively back and advise startups operating at the intersection of technology and finance. An early believer in digital assets, Dr. Kidwai has been investing in crypto and blockchain since 2016. His operating experience includes founding Real Time Content, a dynamic media personalization platform that was acquired by NASDAQ-listed Pitney Bowes. Earlier in his career, he held investment roles at Edge Venture Capital and AtomicTangerine, a venture consultancy spun out of SRI International. Dr. Kidwai holds a B.Sc. (Hons) in Technology Management from Staffordshire University and honorary doctorates from both Lincoln University and Staffordshire University. Company Bio C1 Fund (NYSE: CFND) C1 Fund Inc. is a closed-end investment fund designed to give investors access to the private digital asset ecosystem. Managed by C1 Advisors, the fund targets a handpicked portfolio of the leading, late-stage private companies driving the future of digital asset services and technology. C1 Fund is built for investors seeking more than market exposure — it offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the leading private companies with the safeguards of a NYSE listed fund that is regulated and liquid. With a disciplined focus on innovation, scale, and institutional-grade governance, C1 Fund positions investors at the forefront of digital asset evolution. For more information about C1 Fund, please visit the Company’s website at www.c1fund.com.

  4. Oct 5

    This CEO Is Disrupting Competitive Gaming, Advertising, & Game Development – Meet Andrew Paradise $FIRY

    Guest Andrew Paradise - Founder & CEO – FIRY Company FIRY Inc. (NYSE:FIRY) Website: http://www.firy.com Andrew's Bio Andrew Paradise, FIRY’s Chief Executive Officer and Founder, is the inventor of real-money skill-based gaming and founded Skillz in 2012. Under his leadership, Skillz became the first publicly traded mobile esports platform and a global leader in mobile gaming, hosting billions of tournaments and distributing millions of dollars in prizes each month. Paradise holds more than 90 issued patents spanning matchmaking algorithms, fraud detection, real-time competition systems, and skill-based gaming infrastructure. Under Paradise’s leadership, FIRY is focuses on advancing its technology platforms and expanding opportunities across competitive gaming, AI-powered advertising, and game-development infrastructure. In 2026, the company also advanced its platform strategy through the integration of Beamable technology, designed to provide developers with enhanced backend, live-operations, and monetization capabilities. To learn more, visit FIRY Inchttp://www.firy.com. Company Bio FIRY Inc. (NYSE:FIRY) is a technology company focused on building platforms that power the future of competitive gaming, advertising technology, and game development. Formerly known as Skillz Inc., the company completed its rebrand to FIRY in 2026 as part of a broader restructuring that brings together three businesses: Skillz, RZR, an AI-powered advertising technology platform, and Beamable, a live-operations and developer platform.

  5. Sep 3

    This CEO is Fighting Parkinson’s And Other Neuro-Degenerative Diseases – Meet Gain Therapeutics GANX CEO

    This CEO is Fighting Parkinson’s And Other Neuro-Degenerative Diseases – Meet Gain Therapeutics GANX CEO Guest: Gene Mack, CEO, Gain Therapeutics Guest’s Bio: Gene Mack serves as Chief Executive Officer and President of Gain Therapeutics. He joined the Company in April 2024 and brings 25 years of experience in the life sciences sector spanning clinical research, financing and capital markets, investing, corporate strategy and business development. Prior to joining Gain, Gene was CFO at privately held Imcyse SA between 2021 and 2023. Previous to Imcyse, Gene was CFO at OncoC4, a privately held biotechnology company that spun out of Merck & Co’s (MSD) $475 million acquisition of OncoImmune in 2020 where he had also been CFO. Before that, he has held the CFO role for several development- and commercial-stage biopharmaceutical companies, raising over $350 million in IPO and other equity transactions. Prior to his operational experience, Gene covered the biotechnology and life sciences sector as a senior publishing analyst at various investment banks, including Gruntal & Co, Lazard, Mizuho, and HSBC. Gene received both his B.S. in Biochemistry and M.B.A. in Finance from Fordham University. Company: Gain Therapeutics ($GANX) Company Description: Gain Therapeutics, a clinical-stage biotechnology company headquartered in Bethesda focused on developing novel allosteric small molecule therapies for neurodegenerative diseases. Under Gene’s leadership, the company is advancing its lead candidate, GT-02287, with recent Phase 1b data presented at AD/PD 2026 demonstrating encouraging biomarker improvements, including reductions in DDC and glucosylsphingosine, as well as durable clinical outcomes through 150 days of treatment in Parkinson’s disease.

  6. Aug 19

    Learn How This $3B Firm Serves Both Individual and Institutional Investors - Meet Cory Krebs

    Guest Cory S. Krebs, CFA CooksonPeirce President and Chief Executive Officer Company CooksonPeirce Website https://cooksonpeirce.com/ AUM Over $3B AUM About Cory Cory S. Krebs, CFA President and Chief Executive Officer As president and chief executive officer for CooksonPeirce, Cory Krebs is tasked with defining corporate strategy and executing the firm’s business plan. Cory is also a member of the firm’s portfolio management team, tasked with the administration of all CooksonPeirce investment strategies, including the Catalyst Dynamic Alpha Fund. Prior to joining CooksonPeirce in 2003, Cory spent five years with Laurel Capital Advisors, an investment subsidiary of Mellon Financial, where he was responsible for all aspects of block order trading, participated in new product development, and assisted in the investment manager due diligence process. Before that, he served in a variety of positions at Federated Investors and American Express Financial Advisors. Cory earned a B.A. in economics and an M.B.A. from the University of Pittsburgh. He also attained the designation of Chartered Financial Analyst from the CFA Institute. He is a member of the CFA Institute and the CFA Society of Pittsburgh. He is also a member of the Pittsburgh Society of Investment Professionals, where he has served on the board of directors and as president of the organization. A proud honors graduate, Cory is a lifetime member of the University of Pittsburgh Alumni Association and the Panther Club. He lives in the South Hills with his wife and three school-aged children. About CooksonPeirce CooksonPeirce, registered in 1984, serves 47 states with a licensed staff of 10 advisors. Headquartered in Pittsburgh, PA, with satellite offices in Ohio, South Carolina, and Florida, CooksonPeirce manages over $3 billion and provides investment advisory services for more than 1,200 clients. Important Disclosures Investing involves risk, including possible loss of principal. Investment decisions are subject to market, currency, economic, and business risks and will not always be profitable. There is no guarantee that risk can be successfully mitigated or otherwise avoided. Nothing herein is an offer to buy or a suggestion to sell securities. Statements using "if," "may," "can," "should," or "will" may be forward looking and are not intended as an opinion, projection, or estimate regarding the market, CooksonPeirce, or its products. AUM of $3 billion as of June 30, 2026, subject to change. CooksonPeirce & Co., Inc. is an SEC registered investment adviser. Registration does not imply a certain level of skill or training. See Form ADV at adviserinfo.sec.gov.

  7. Aug 11

    This Biotech CEO Is Creating A Cure For Type 1 Diabetes -Meet The CEO Of Eledon Pharma - $ELDN

    Guest Full Name: Dr. David-Alexandre (“DA”) C. Gros, MD CEO DA’s Bio: Dr. Gros has served as Chief Executive Officer and a member of the Board of Directors of Eledon Pharmaceuticals, Inc. since September 2020. He joined Eledon Pharmaceuticals from Imbria Pharmaceuticals Inc., where he served as Co-Founder, Chief Executive Officer and Chairman of the Board of Directors. Prior to Imbria, Dr. Gros was President and Chief Operating Officer of Neurocrine Biosciences, Inc., Chief Business and Principal Financial Officer of Alnylam Pharmaceuticals, Inc., and Chief Strategy Officer of Sanofi, S.A. Before joining Sanofi, Dr. Gros held leadership positions in healthcare investment banking at Centerview Partners, LLC, and Merrill Lynch, Pierce, Fenner & Smith Inc., and in healthcare consulting at McKinsey & Company. He previously served on the Board of Directors of Eliem Therapeutics, Inc., a biotechnology company which he co-founded, and is currently the Executive Chairman of Saint Jean Groupe, S.A., a leading French manufacturer of pasta products since 1935. Dr. Gros earned his Doctor of Medicine from The Johns Hopkins University School of Medicine, a Master of Business Administration from Harvard Business School, and a Bachelor of Arts from Dartmouth College. Company: Eledon Pharmaceuticals, Inc. Ticker: ELDN Website: https://eledon.com/ About the Company: Eledon Pharmaceuticals, Inc. is a clinical stage biotechnology company that is developing immune-modulating therapies for the management and treatment of life-threatening conditions. The Company’s lead investigational product is tegoprubart, an anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential. The central role of CD40L signaling in both adaptive and innate immune cell activation and function positions it as an attractive target for non-lymphocyte depleting, immunomodulatory therapeutic intervention. The Company is building upon a deep historical knowledge of anti-CD40 Ligand biology to conduct preclinical and clinical studies in kidney allograft transplantation, xenotransplantation, islet cell transplantation, and amyotrophic lateral sclerosis (ALS). Eledon is headquartered in Irvine, California.

4.9
out of 5
15 Ratings

About

This show interviews the “smart money” (large money managers & CEOs) for timeless investing advice. My goal is to provide you with timeless/actionable advice that you can use to make smarter investment decisions, and help you become intellectually wealthy. The Host: Adam Sarhan, Author, Investor, and Forbes Contributor, interviews real money managers with over $100 million in assets under management (AUM) and CEOs for timeless advice. Disclaimer: All our work is general in nature and for educational/informational purposes only. No specific investment advice is given.

You Might Also Like